Enhertu as Second-Line Therapy for HER2-Positive Advanced Gastric Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On September 18, 2021, AstraZeneca announced the results of the DESTINY-Gastric02 Phase 2 clinical trial, evaluating Enhertu (Trastuzumab deruxtecan) as a second-line therapy for patients with HER2-positive advanced gastric cancer. The findings were presented at the ESMO Congress 2021.
Study Design: DESTINY-Gastric02 Trial
DESTINY-Gastric02 is an international, multicenter, open-label, single-arm Phase 2 trial. It enrolled patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) cancer who had progressed on or after a trastuzumab-containing regimen.
Patients received Enhertu at a dose of 6.4 mg/kg every three weeks. The primary endpoint was objective response rate (ORR).
Key Efficacy Results (Median Follow-up 5.7 Months)
- Objective Response Rate (ORR): 38.0%
- Complete Response (CR): 3.8%
- Partial Response (PR): 34.2%
- Disease Control Rate (DCR): 81.0%
- Median Duration of Response (DOR): 8.1 months
- Median Progression-Free Survival (PFS): 5.5 months
Safety Profile
The safety profile was consistent with previous trials of Enhertu. The most common Grade 3 or higher adverse events included:
- Anemia: 7.6%
- Neutropenia: 7.6%
- Interstitial Lung Disease (ILD): 7.6% (N=6 patients)
- Nausea and Fatigue: 3.8% each
Most adverse events were Grade 1 or 2.
Conclusion
Dr. Eric Van Cutsem from University Hospitals Leuven concluded that Enhertu demonstrates a clinically meaningful response in patients with HER2-positive advanced gastric cancer who have failed prior treatment, establishing its role as a potent second-line option.
Source: AstraZeneca Press Release - DESTINY-Gastric02 Results
#GastricCancer #HER2Positive #Enhertu #TDXd #DESTINYGastric02 #CancerResearch
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4